AMRI, a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life, will present several scientific posters at the 2017 AAPS Annual Meeting, Nov. 12-15, 2017, in San Diego.
AMRI will be featuring its complete suite of capabilities at the conference, including but not limited to, integrated drug discovery services, formulation and chemical development solutions, as well as development and manufacturing expertise for API and sterile drug products.
Noteworthy posters and presentations include:
Tuesday, Nov. 14, 4-5 p.m.
Excipient Compatibility Studies by Isothermal Calorimetry (IsoCal) This study demonstrates that IsoCal provides a quick and easy approach to identify potential incompatibility between API and excipients.
In Vitro Bioequivalence Method Development for Sucroferric Oxyhydroxide AMRI scientists developed an in vitro method to ascertain bioequivalence of the drug sucroferric oxyhydroxide. Because the drug is not absorbed in the body, the only way to assess bioequivalence, which is important for the development of potential generic versions of the drug, is to do so using in vitro methods.
Wednesday, Nov. 15, 10-11 a.m.
Robustness of Drug Release from Transdermal Patches The purpose of this study was to illustrate the ruggedness of drug release from a nicotine transdermal system patch when subjected to various potential misuse conditions, by measuring the impact of these conditions on the in vitro release profile of the product.
AMRI, a global contract research and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life. With locations in North America, Europe and Asia, AMRI’s team combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development, Analytical and Solid State Services, API Manufacturing and Drug Product. For more information about AMRI, visit www.amriglobal.com.